United Therapeutics
UTHR Nasdaq· Biotechnology
Last close · Oct 26, 2026
$592.84
KIRA · Stoqly’s AI analyst, in plain words
- United Therapeutics had $3.2B of revenue in fiscal 2025, up 10.6% on the year before. Over five years, revenue changed +16.5% a year on average.
- Its operating margin was 46.9%, down 1.0 pts: of every 100 in sales, about 47 is left after running the business.
- United Therapeutics made $1.3B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 6.9% a year.
- Free cash flow was $1.0B in fiscal 2025, 32.7% of revenue.
- United Therapeutics returned $1.0B to shareholders in fiscal 2025, 96% of free cash flow. The diluted share count fell 1.2%.
Market cap
$27.2B
P/E
21.2x
Revenue
$3.2B
Net income
$1.3B
Free cash flow
$1.0B
Operating margin
46.9%
United Therapeutics in 30 seconds · fiscal 2025
Are sales growing?
+10.6%
Yes. Sales grew 10.6% last year.
Does it make a profit?
41.9%
Yes. It keeps 41.9% of every sale as profit.
Does profit turn into cash?
32.7%
Yes. 32.7% of sales ends up as free cash.
How is the share priced?
21.2x
One share costs 21.2 times its yearly profit per share. Typical for its sector: 28.4x.
What United Therapeutics does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- United Therapeutics Corporation
- CIK
- 0001082554
United Therapeutics · UTHR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B |
| Revenue growth | 13.6% | 14.9% | 20.2% | 23.6% | 10.6% |
| Gross margin | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| Operating margin | 33.0% | 50.6% | 50.9% | 47.9% | 46.9% |
| Net income | $476M | $727M | $985M | $1.2B | $1.3B |
| Net margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| Diluted EPS | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Cash | |||||
| Cash from operations | $598M | $803M | $978M | $1.3B | $1.6B |
| Capital expenditure | $121M | $139M | $230M | $247M | $521M |
| Free cash flow | $477M | $664M | $748M | $1.1B | $1.0B |
| FCF margin | 28.3% | 34.3% | 32.1% | 37.6% | 32.7% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $1.0B | $1.0B |
| Share count change | 6.1% | 2.5% | 2.5% | −2.4% | −1.2% |
| Debt and strength | |||||
| Cash and short-term investments | $1.9B | $2.8B | $3.0B | $3.3B | $2.9B |
| Shareholders' equity | $4.0B | $4.8B | $6.0B | $6.4B | $7.1B |
| Current ratio | 7.6x | 9.9x | 4.4x | 5.3x | 6.6x |
| Interest coverage | 29.9x | 30.2x | 20.0x | 32.1x | 76.5x |
| Returns and quality | |||||
| Return on equity | 12.9% | 16.6% | 18.3% | 19.2% | 19.7% |
| Altman Z'' | 9.4 | 11.1 | 11.7 | 14.6 | 16.9 |
Insiders bought, 12 months
$0.9M
1 insider
Insiders sold, 12 months
$984M
8 insiders
Of sales under plans
100%
$983M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
United Therapeutics · UTHR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| United Therapeutics UTHR | $27.2B | 10.6% | 46.9% | 32.7% | — | 21.2x | — |
| BioMarin Pharmaceutical BMRN | $10.8B | 12.9% | 12.7% | 22.5% | 5.8% | 150.7x | 5 |
| Neurocrine Biosciences NBIX | $15.2B | 21.5% | 21.6% | 26.2% | 25.6% | 21.4x | 6 |
| Fortrea FTRE | $2.3B | 1.0% | −32.0% | 3.2% | −36.2% | — | — |
| Exelixis EXEL | $16.9B | 7.0% | 37.6% | 37.8% | 64.9% | 20.5x | 6 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $592.84 a share, the company is worth $27.2B: 21.2 times its earnings of the last four quarters.
United Therapeutics grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 1 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001082554). Data updated October 16, 2026. For information only — not investment advice. Check the original filings before relying on any figure.